INS and diabetes mellitus: Fourth, the TOPCAT Americas data have been published separately, although these account for only 21% of the total patients in the present data set in which we have conducted more comprehensive analyses.15 Finally, data on the type and dose of insulin (and other glucose‐lowering therapies), the level of glycaemic control (e.g. measurement of glycated haemoglobin), and burden of microvascular complications in patients with diabetes were not available.